CN Patent

CN108473587A — 用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合

Assigned to Pfizer Inc · Expires 2018-08-31 · 8y expired

What this patent protects

本公开内容描述了包含OX40的激动剂和4‑1BB的激动剂的联合治疗，以及联合治疗在治疗癌症中的用途。

USPTO Abstract

本公开内容描述了包含OX40的激动剂和4‑1BB的激动剂的联合治疗，以及联合治疗在治疗癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN108473587A
Jurisdiction
CN
Classification
—
Expires
2018-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.